MTOR and breast carcinoma: As a natural bioactive compound, shikonin specifically inhibits the overactivation of the mTOR signaling pathway and effectively downregulates the expression of its key downstream effector gene, CCND1. Reduced expression of CCND1, a critical regulator of the cell cycle, leads to a significant decrease in breast cancer cell proliferation (Figure 7).